Jiangxi Synergy Pharmaceutical Co.Ltd(300636) independent director
On matters related to the fourth meeting of the third board of directors of the company
separate opinion
In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, and the guidelines for the standardized operation of GEM listed companies of Shenzhen Stock Exchange As an independent director of Jiangxi Synergy Pharmaceutical Co.Ltd(300636) (hereinafter referred to as “the company”), we, in line with the principle of being responsible to the company and all shareholders of the company, consult the relevant materials provided by the company After understanding the relevant situation, based on the independent, objective and fair judgment position, we have reviewed the relevant proposals considered at the fourth meeting of the third board of directors of the company and expressed the following independent opinions: I. independent opinions on adjusting the implementation progress of the company’s investment projects with raised funds
We believe that the company’s plan to adjust the implementation progress of the “phase I project of annual output of 100 tons of 7-methoxynaphthone, 30 tons of rivaroxaban and other APIs and 2 billion tablets (tablets) oral solid preparations” is a prudent decision made by the company according to the actual progress of the project, which is in line with the actual situation of the company and will not have a substantive impact on the implementation of the raised investment project, There is no change or disguised change in the purpose of the raised funds and damage to the interests of the company and shareholders, especially minority shareholders. The above matters have fulfilled the necessary deliberation procedures, and the contents and procedures comply with laws and regulations such as the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the guidelines for the standardized operation of GEM listed companies of Shenzhen Stock Exchange, the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies Normative documents and relevant provisions of the company’s measures for the administration of raised funds. We unanimously agree that the company will adjust the implementation progress of the investment project with raised funds. (there is no text below, which is the signature page)
(there is no text on this page, which is the signature page of Jiangxi Synergy Pharmaceutical Co.Ltd(300636) independent director’s independent opinions on matters related to the fourth meeting of the third board of directors) signature of independent director: Li Guoping (signature): Peng Yiyuan (signature): Peng Xin (signature):
January 11, 2002
